Skip to main content
ZoetisNews

Zoetis receives FDA approval for dog treatment: what it means for Zoetis stock

Source: Autobound Signal API · 77 signals tracked for Zoetis · updated

Get Zoetis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Zoetis this week? Use Autobound signals for zoetis.com.

What happened

Zoetis appointed Iris Knobloch to its board, effective December 1, 2026.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Zoetis Inc. (US98978V1035) received U.S. Food and Drug Administration approval on October 20, 2026, for Convenia RTU for Dogs, an injectable treatment that can provide up to 14 days of antibiotic therapy. The company is scheduled to report third-quarter results on November 5, 2026. According to Zoetis, Convenia RTU is intended for susceptible bacterial skin infections in dogs and is administered by a veterinary professional. The company expects the product to become available to veterinarians in the first quarter of 2027. The treatment extends the company's companion-animal product offering with a single-injection format for dogs of all sizes. That commercial angle matters as pricing power has become a central concern for the stock. On October 20, 2026, Jefferies downgraded Zoetis to Hold from Buy and cut its price target from USD 103 to USD 83, a 19.42 percent reduction, according to Markets Insider. The firm cited a softer pricing environment and limited visibility on future margin expansion. Zoetis declared a fourth-quarter 2026 dividend of USD 0.53 per share on October 8, 2026, according to Business Wire. It appointed Iris Knobloch to its board effective December 1, 2026, on October 13, 2026, as reported by Business Wire . The October 20 FDA approval is the latest of the three events. The dividend record and ex-dividend date is October 30, 2026, while the next...

Keep reading with a free account

The rest of this article, and every signal for Zoetis, is in your free account.

Extracted by Autobound

From the Signal API record
Event
News

What this signalsA new leader often reviews the tools the team uses.

Person
Iris KnoblochBoard Member
Takes effect
Dec 1, 2026

The full record

From the Signal API record

People

  • Iris KnoblochBoard Member · Named in the story

Topics and mentions

Job title tags

  • directors

Extraction

Confidence
90%
Detected
Oct 25, 2026
signal_type
news
signal_subtype
hires

Use this data

Get every news signal for Zoetis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Zoetis this week?”

  2. Send it to your own tools

    The Signal API returns news signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/3ff765a0-97c1-be64-ec5b-53b5d31b9636 returns this record as JSON. POST /v1/companies/enrich returns every signal for zoetis.com.

{
  "signal_id": "3ff765a0-97c1-be64-ec5b-53b5d31b9636",
  "signal_type": "news",
  "signal_subtype": "hires",
  "detected_at": "2026-10-25T12:38:06+00:00",
  "company": {
    "name": "Zoetis",
    "domain": "zoetis.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/zoetis-receives-fda-approval-for-dog-treatment-what-it-means-for-zoetis-stock/70408883",
    "title": "Zoetis receives FDA approval for dog treatment: what it means for Zoetis stock - ad-hoc-news.de",
    "contact": "Iris Knobloch",
    "excerpt": "Zoetis Inc. (US98978V1035) received U.S. Food and Drug Administration approval on October 20, 2026, for Convenia RTU for Dogs, an injectable treatment that can provide up to 14 days of antibiotic therapy. The company is scheduled to report third-quarter results on November 5, 2026. According to Zoetis , Convenia RTU is intended for susceptible bacterial skin infections in dogs and is administered by a veterinary professional. The company expects the product to become available to veterinarians in the first quarter of 2027. The treatment extends the company's companion-animal product offering with a single-injection format for dogs of all sizes. That commercial angle matters as pricing power has become a central concern for the stock. On October 20, 2026, Jefferies downgraded Zoetis to Hold from Buy and cut its price target from USD 103 to USD 83, a 19.42 percent reduction, according to Markets Insider . The firm cited a softer pricing environment and limited visibility on future margin expansion. Zoetis declared a fourth-quarter 2026 dividend of USD 0.53 per share on October 8, 2026, according to Business Wire . It appointed Iris Knobloch to its board effective December 1, 2026, on October 13, 2026, as reported by Business Wire . The October 20 FDA approval is the latest of the three events. The dividend record and ex-dividend date is October 30, 2026, while the next quarterly...",
    "summary": "Zoetis appointed Iris Knobloch to its board, effective December 1, 2026.",
    "planning": true,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2405021_1920_1080.webp",
    "job_title": "Board Member",
    "confidence": 0.9,
    "published_at": "2026-10-25T12:38:06Z",
    "effective_date": "2026-12-01",
    "job_title_tags": [
      "directors"
    ],
    "article_sentence": "It appointed Iris Knobloch to its board effective December 1, 2026, on October 13, 2026, as reported by Business Wire ."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.